BODIPY last trial...

• Messages sorted by: [ date ][ thread ][ subject ][ author ]
• Next message: tchadderton@smtpgate.octrf.on.ca: "Topoisomerase 11 alpha"
• Previous message: Helene Paxton: "3rdAnnual Clinical Symposium Correction"

About 2 weeks ago I posted a message asking whether anybody was using BODIPY
instead of FITC with neutralite. Nobody responded...
When we asked Molecular Probes for papers on BODIPY they could just come up
with one single paper, dealing in fact marginally with BODIPY.

So is it that nobody is using BODIPY? So then why is Molecular probe still
manufacturing it if it has no obvious advantage over FITC?

Any help will be greatly appreciated.

Daniel VAULOT
______________________________________
Daniel VAULOT
Station Biologique
BP 74
29682 Roscoff Cx
FRANCE
Ph: (33) 98 29 23 34
Fax: (33) 98 29 23 24
e-mail: vaulot@sb-roscoff.fr
W3: http://www.sb-roscoff.fr (PhytoPlankton Group)

• Next message: tchadderton@smtpgate.octrf.on.ca: "Topoisomerase 11 alpha"
• Previous message: Helene Paxton: "3rdAnnual Clinical Symposium Correction"

CD ROM Vol 2 was produced by staff at the Purdue University Cytometry Laboratories and distributed free of charge as an educational service to the cytometry community. If you have any comments please direct them to Dr. J. Paul Robinson, Professor & Director, PUCL, Purdue University, West Lafayette, IN 47907. Phone:(317) 494-0757; FAX (317) 494-0517; Web http://www.cyto.purdue.edu EMAIL robinson@flowcyt.cyto.purdue.edu